MacroGenics sells rights for two autoimmune disorder candidates

11 May 2018
2019_biotech_test_vial_discovery_big

US biotech MacroGenics (Nasdaq: MGNX) has inked deals with Provention Bio involving two clinical-stage assets. Provention has acquired all rights to teplizumab, to be further developed as PRV-031, and licensing rights to MGD010 for development as PRV-3279.

"Our agreements with MacroGenics expand Provention's pipeline with two additional clinical-stage assets that align perfectly with our mission to intercept or prevent immune-mediated diseases," explained Ashleigh Palmer, co-founder and chief executive of Provention Bio, adding: "In less than a year since announcing our founding financing, Provention has secured five clinical stage assets in the burgeoning field of disease prevention and interception."

"Given MacroGenics' current focus on its immuno-oncology pipeline, we believe Provention Bio will be an excellent partner to progress these programs and potentially bring these innovative medicines to patients suffering from serious autoimmune disorders," explained Scott Koenig, president and chief executive of MacroGenics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology